The EUROCARE study, the largest population-based study of survival in European blood cancer patients to date, analyzed data from 30 cancer registries, involving all patients with cancer diagnoses in 20 European countries.
Scientists have developed a test which accurately predicts the prognosis for patients with the most common form of leukemia.
An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.
Scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast cancer.
Cancer cells decide whether to live or die after a short period of intense exposure to targeted therapy, opposing the current requirement for continuous treatment, according to a new study.
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|